Anthos Therapeutics, based in Cambridge, has a drug in late-stage clinical trials aimed at preventing strokes and blood clots ...

Sato, Vicki, Christoph Jaeker, and Pooja Mehta Solanki. "China Novartis Institute for Biomedical Research: Building a Sustainable, Globally Integrated Research Enterprise." Harvard Business School ...

As president of the Novartis Institutes for BioMedical Research, or NIBR, Bradner leads the company's drug research and discovery. But, speaking at the World Economic Forum in Davos, Switzerland ...

Jay Bradner, president of the Novartis Institutes for Biomedical Research (NIBR), is retiring from the position after seven years in the role, and will be replaced by Merck & Co R&D executive ...

One year ago this week, Novartis biomedical research president Fiona Marshall called artificial intelligence a technology with “the potential to transform how we discover new drugs.” ...

President of the Novartis Institutes for Biomedical Research, felt that the time was right to move into this region. So Mark and I went to look at the site where the institute is going be — at ...

In the same year, it also created the Novartis Institutes for BioMedical Research (NIBR), which headquarters in the US. In 2003, Novartis acquired the worldwide adult medical nutrition business of ...

Undaunted by the controversy over its $50 million deal to fund agricultural research at the University of California at Berkeley (UCB) a year ago, the Swiss company Novartis has recently announced ...